Parecoxib
From Wikipedia, the free encyclopedia
 |
|
|
Parecoxib
|
|
| Systematic (IUPAC) name | |
| N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl] sulfonyl}propanamide |
|
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| Chemical data | |
| Formula | C19H18N2O4S |
| Mol. mass | 370.422 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | 98% |
| Metabolism | Hepatic to valdecoxib and propionic acid CYP extensively involved (mainly CYP3A4 and 2C9) |
| Half life | 22 minutes (parecoxib) 8 hours (valdecoxib) |
| Excretion | Renal (70%, metabolites) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
Not recommended |
| Legal status | |
| Routes | Intravenous and intramuscular |
Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.
|
||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
